文献速递脊柱关节炎

银屑病关节炎生物制剂与靶向治疗的比较有效性

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis.
PubMed 文献 · RMD Open · 2021-01-01

结果显示,在生物制剂初治患者中IL-12/23拮抗剂有效性低于TNF-α抑制剂(aRR 0.63,95%CI 0.45-0.89),在生物制剂经治患者中PDE4抑制剂有效性低于TNF-α抑制剂(aRR 0.67,95%CI 0.46-0.96)。

要点

  • 生物制剂初治PsA患者中,IL-12/23拮抗剂有效性低于TNF-α抑制剂。
  • 生物制剂经治PsA患者中,PDE4抑制剂有效性低于TNF-α抑制剂。
  • 各治疗组符合有效性标准的比例:TNF-α 32.3%、IL-17A 29.0%、PDE4 25.6%、IL-12/23 19.3%。

核心结论

  • TNF-α抑制剂在生物制剂初治患者中似乎比IL-12/23拮抗剂更有效。
  • TNF-α抑制剂在生物制剂经治患者中似乎比PDE4抑制剂更有效。

研究设计与样本

  • 回顾性队列研究,采用针对炎症性关节炎治疗验证的去标识化理赔算法。
  • 采用按既往生物制剂暴露分层的Poisson回归(稳健方差)并调整潜在混杂因素。

主要发现

  • 2730例患者中,IL-12/23拮抗剂组327例、IL-17A拮抗剂组138例、PDE4抑制剂组624例、TNF-α抑制剂组1641例。
  • 符合有效性标准的比例:IL-12/23组63例(19.3%)、IL-17A组40例(29.0%)、PDE4组160例(25.6%)、TNF-α组530例(32.3%)。
  • 生物制剂初治患者中,IL-12/23拮抗剂与TNF-α抑制剂相比的完全调整相对风险(aRR)为0.63(95%CI 0.45-0.89)。
  • 生物制剂经治患者中,PDE4抑制剂与TNF-α抑制剂相比的aRR为0.67(95%CI 0.46-0.96)。

关键数值与推荐

  • 有效性基于以下指标:依从性、添加或转换生物制剂或PDE4抑制剂、新增非生物制剂改善病情抗风湿药、增加生物制剂或PDE4抑制剂剂量或频率、以及糖皮质激素使用。
  • 主要结局为符合有效性算法的百分比。

临床怎么用

  • 研究结果可帮助指导银屑病关节炎患者的治疗选择。
  • 对于生物制剂初治患者,TNF-α抑制剂可能比IL-12/23拮抗剂更有效。
  • 对于生物制剂经治患者,TNF-α抑制剂可能比PDE4抑制剂更有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To quantify comparative effectiveness of interleukin (IL)-12/23 antagonist (ustekinumab), IL-17A antagonists (secukinumab and ixekizumab), PDE4 inhibitor (apremilast) and tumour necrosis factor-alpha (TNF-α) inhibitors (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab) for psoriatic arthritis (PsA). METHODS: We adapted a deidentified claims-based algorithm validated for inflammatory arthritis treatments to compare treatments among a retrospective cohort of commercially insured and Medicare Advantage beneficiaries with PsA from October 2013 to April 2019 in the OptumLabs Data Warehouse. Main outcomes include (1) treatment effectiveness, based on: adherence, adding or switching biologic or PDE4, addition of new non-biologic disease-modifying antirheumatic drug, increase in biologic or PDE4 dose or frequency and glucocorticoid use and (2) percentage of each group fulfilling the effectiveness algorithm. We used Poisson regression with robust variance stratified by prior PsA biologic exposure and adjusted for potential confounders. RESULTS: Of 2730 individuals with PsA, 327 received IL-12/23, 138 IL-17A's, 624 PDE4 and 1641 TNF-α's. Effectiveness criteria were fulfilled among 63 (19.3%) IL-12/23 recipients, 40 (29.0%) IL-17A recipients, 160 (25.6%) PDE4 recipients and 530 (32.3%) TNF-α recipients. Among biologic-naïve individuals, IL-12/23 was less effective than TNF-α's with fully adjusted relative risk (aRR) compared with TNF-α's of 0.63 (95% CI 0.45 to 0.89). Among biologic-experienced individuals, PDE4 recipients were less effective than TNF-α's (aRR 0.67, 95% CI 0.46 to 0.96). CONCLUSIONS: TNF-α's appeared more effective than IL-12/23's for biologic-naïve individuals, and PDE4's for biologic-experienced individuals. These results may help inform treatment choice for individuals with PsA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Zhang H, Wen J, Alexander GC, et al. Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. RMD Open. 2021. PMID: 33863840. doi:10.1136/rmdopen-2020-001399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。